Navigation Links
Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Date:2/4/2009

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:

    Corporate Presentation:
    Date:  Monday, February 9, 2009
    Time:  3:45 p.m. - 4:15 p.m. Eastern
    Location: Waldorf Astoria, Astor Room, New York
    Speaker: Graham Cooper, Chief Financial Officer

    Panel Discussion:
    Feeding the Need for New Treatments in Obesity
    Date:  Monday, February 9, 2009
    Time:  11:00 a.m. - 12:10 p.m. Eastern
    Location: Waldorf Astoria, East Foyer, New York
    Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
2. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
3. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
8. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
9. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... BURLINGAME, Calif. , April 16, 2015  Scientists ... session, "New Drugs on the Horizon," at the American ... Philadelphia, PA on Sunday, April 19, ... , Ph.D., Cleave,s Director of Biology, will present new ... CB-5083, a first-in-class, oral inhibitor of p97, a critical ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... MUMBAI, India, Aug. 25 ,Codexis, Inc., a ... a leading Indian active pharmaceutical ingredients (APIs) ... strategic,collaboration, expanding their three-year partnership in pharmaceuticals,manufacturing., ... will offer multiple pharmaceutical,intermediates and active pharmaceutical ...
... DETROIT, Aug. 25 For the first time in ... highly sophisticated,3D robotics through a single incision., "We ... us to,perform this type of procedure routinely," says Craig ... performed the delicate,operation last week using the da Vinci ...
... Vice President of Commercial Operations,and James Briggs Senior ... Aug. 25 Ikaria Holdings, Inc., a fully,integrated ... two key executives. Stephen A. Ross was appointed ... was named Senior Vice,President for Human Relations., ...
Cached Biology Technology:Codexis, Arch Announce Expanded Collaboration 2Codexis, Arch Announce Expanded Collaboration 3State's First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital 2Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... lab tests of "killer paper," a material intended for ... preserve foods by fighting the bacteria that cause spoilage. ... contains a coating of silver nanoparticles, which are powerful ... that silver already finds wide use as a bacteria ...
... Basque Institute for Agricultural Research and Development) have ... of infection by visna/maedi virus. This is a ... pneumonia, mastitis and neurological disorders. The study confirmed ... of the virus is the most likely path ...
... apple growers in the northeastern United States are faced ... tree nutrition and crop load. These and other problems ... (IFP) and organic fruit production (OFP) of apples, limiting ... recent issue of HortScience , Cornell University scientists ...
Cached Biology News:Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus 2Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus 3Integrated, organic production systems evaluated for 'liberty' apple 2
Normal serum collected from healthy Kunming mice....
Request Info...
... involves the optimization of immunostaining. ... of the primary antibody, selection ... (e.g. Alk. Phos., HRP, fluorescence, ... detection, evaluation by light or ...
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Biology Products: